Newborn Screening

What is Newborn Screening?

Newborns and children under 24 months presenting with life-threatening conditions need a fast and precise diagnosis to ensure rapid and efficient further diagnostic and therapeutic initiation. Up to one-third of all babies and children admitted to the ICU have a genetic disease. For many of them early identification can make the difference for their immediate and later health
CentoICU® is a comprehensive NGS panel that includes more than 800 genes, explicitly selected for the genetic testing of critically ill newborns and children under 24 months. It is designed to address multiple genetic conditions that may present in the newborn or first childhood period, many with overlapping phenotypes and immediate implications for treatment initiation. It allows clinicians to utilize just one single test to provide an accurate diagnosis of newborn-related diseases.

 

CentoICU® is indicated for newborns and children under 24 months admitted to the ICU and presenting with unclear symptomatology which can be part of a genetic condition, i.e.

  • Bleeding dyathesis.
  • Blood abnormalities (anemia).
  • Bone fragility.
  • Failure to thrive.
  • Heart abnormality/arrhythmia.
  • Hepatospenomegaly.
  • Hypotonia.
  • Ichthyosis/epidermolysis bullosa.
  • Metabolic abnormalities.
  • Microcephaly.
  • Neutropenia.
  • Abnormal newborn screening results.
  • Respiratory failure.
  • Skeletal abnormalities/craniosynostosis.
  • Skin fragility.
  • Unclear seizures.